Database : HANSEN Search on : DAPSONA [Subject descriptor] References found : 210 [refine] Displaying: 1 .. 20   in format [Detailed]

page 1 de 11

go to page

1 / 210

HANSEN

select to print

Id: 19947 Author: Pavithran, K; Satish, T. C. Title: Dapsone-induced motor polyneuropathy in a patient with leprosy. Source: Int. J. Lepr;65(2):262-263, Jun. 1997. . Descriptors: Hanseníase Dimorfa/quimioter Dapsona/ef adv Dapsona/uso terap Doença dos Neurônios Motores/ind quim Doença dos Neurônios Motores/diag Limits: Humanos Masculino Feminino Location: BR191.1

2 / 210

HANSEN

select to print Texto Completo-en

Id: 19757 Author: Girdhar, Anita; Mishra, Brajendra; Lavania, Ravinder K; Bagga, Ashok K; Malaviya, Govind N; Girdhar, Bhawneshwar K. Title: Leprosy in infants - report of two cases. Source: Int J Lepr;57(2):472-475, June 1989. ^bilus. Descriptors: Hanseníase/diag Hanseníase/quimioter Hanseníase/patol Rifampina/uso terap Dapsona/uso terap Limits: Humanos Feminino Lactente Electronic Medium: http://hansen.bvs.ilsl.br/textoc/revistas/intjlepr/1989/pdf/v57n2/v57n2a04.pdf / en Location: Br191.1

3 / 210

HANSEN

select to print Texto Completo-en

Id: 19755 Author: Katoch, Kiran; Ramanathan, Usha; Natrajan, Mohan; Bagga, Ashok K; Bhatia, AS; Saxena, RK; Ramu, Gopal. Title: Relapses in paucibacillary patients after treatment with three short term regimens containing rifampin. Source: Int J Lepr;57(2):458-464, June 1989. ^btab. Abstract: Three multidrug regimens all containing rifampin and dapsone have been tried for the treatment of 278 cases of paucibacillary leprosy. Regimen I was the one recommended by the WHO Study Group. Regimen II was the same as Regimen I with depsone alone continued for a further 6 months. Regimen III was the same as Regimen II but rifampin was given daily for the first 7 days. The patients were comparable with regard to disease classification, lepromin status, bacteriological status, and number of lesions. As reported earlier, the disease inactivity rates by 1 year of treatment were much greater with Regimens II and III than with Regimen I (94% and 97% vs 76%). Early reaction was seen in 6% of those in Regimen III and in none in Regimens I and II. Late reaction was observed in 9% of those in Regimen I and none in Regimens II and III. During 3 1/2 years of follow up, 13% of the cases in Regimen I, 1% in Regimen II, and 2% in Regimen III relapsed. Since the patients in the three regimens were otherwise comparable, it is concluded that the high inactivity rate, low relapse rate (1%-2%), and no early or late reaction as observed in Regimen II patients were because of adequate treatment^ien. Descriptors: Dapsona/admin Dapsona/uso terap Rifampina/admin Rifampina/uso terap Hanseníase/microbiol Hanseníase/patol Limits: Humanos Masculino Feminino Adulto Electronic Medium: http://hansen.bvs.ilsl.br/textoc/revistas/intjlepr/1989/pdf/v57n2/v57n2a02.pdf / en Location: Br191.1

4 / 210

HANSEN

select to print Texto Completo-en

Id: 19754 Author: Katoch, Kiran; Ramu, Gopal; Ramanathan, Usha; Sengupta, Utpal; Sharma, Vishnu D; Shivannavar, Channappa T; Katoch, Vishwa M. Title: Results of a modified WHO regimen in highly bacilliferous BL/LL patients. Source: Int J Lepr;57(2):451-457, June 1989. ^bgraf, ^btab. Abstract: regimen consisting of 600 mg of rifampin once a month, 100 mg of clofazimine on alternate days, and 100 mg of dapsone daily was used in 56 untreated, highly bacillated borderline lepromatous/lepromatous (BL/LL) patients with an average bacterial index (BI) of 4.45. Treatment was continued until skin-smear negativity. After 2 years of therapy, none of the patients had become smear negative and the average BI was 2.56. There was no growth on inoculation of skin-tissue biopsies in the normal mouse foot pad after 6 months of therapy. Bacillemia was still detectable in 11/50 patients, and significant ATP levels were detected in Mycobacterium leprae from skin-tissue biopsies in 16% of the cases. After 3 years of therapy, three patients had become smear negative. The average BI was 1.30. None of the patients had detectable bacillemia, and 5% of the cases showed detectable ATP levels in M. leprae from tissue biopsies. After 4 years of therapy, 41.7% of the patients had become smear negative. The average BI was 0.66, and no ATP was detected in any of the purified bacillary suspensions. The fall in BI was accelerated, and more patients on continued treatment became negative earlier compared to those having treatment for a limited duration, as reported by others^ien. Descriptors: Clofazimina/admin Clofazimina/uso terap Dapsona/admin Dapsona/uso terap Hanseníase Dimorfa/microbiol Hanseníase Virchowiana/microbiol Limits: Humanos Adolescente Adulto Electronic Medium: http://hansen.bvs.ilsl.br/textoc/revistas/intjlepr/1989/pdf/v57n2/v57n2a01.pdf / en Location: Br191.1

5 / 210

HANSEN

select to print Texto Completo-en

Id: 19744 Author: Agregawala, Javed Naim; Sinha, Sudhir; Ghei, Satish K; Sengupta, Utpal; Katoch, Kiran; Girdhar, Bhawneshwar. Title: Demonstration of antidapsone antibody in leprosy patients. Source: Int J Lep;57(3):687-690, sept. 1989. ^bgraf. Descriptors: Hanseníase/quimioter Hanseníase/imunol Dapsona/uso terap Limits: Humanos Electronic Medium: http://hansen.bvs.ilsl.br/textoc/revistas/intjlepr/1989/pdf/v57n3/v57n3cor01.pdf / en Location: Br191.1

6 / 210

HANSEN

select to print Texto Completo-en

Id: 19705 Author: Chen, Xiang-Sheng; Li, Wen-Zhong; Jiang, Cheng; Ye, Gan-Yun. Title: Studies on risk of leprosy relapses in China: relapses after treatment with dapsone monotherapy. Source: Int. J. Lepr;67(4):371-378, Dec., 1999. tab, graf. Abstract: Based upon the data from the Chinese National System for Leprosy Surveillance, this paper reports on the relapses in 297,343 leprosy patients [multibacillary (MB) 106,518, paucibacillary (PB) 190,825] cured by dapsone monotherapy. A total of 11,055 (MB 8675, PB 2380) patients relapsed during an accumulated follow-up period of 4,229,050 patient-years (PY), giving an overall relapse rate of 3.72 per 100 cases or 2.61 per 1000 PY, i.e., 8.14% or 5.91 per 1000 PY over an average follow-up period of 13.8 +/- 8.4 years in MB patients and 1.25% or 0.86 per 1000 PY over an average period of 14.5 +/- 8.9 years in PB patients. For either the overall relapse rate per 100 cases or per 1000 PY, the differences between MB and PB patients were statistically significant, except during 36-40 years of follow up. For both MB and PB patients, the relapse rates showed consistently significant decreases year by year, particularly in PB patients whose relapse rate per 1000 PY was 1.21 in year 10 of follow up; whereas it remained more than 10 per 1000 PY in MB patients. In view of that, the overall relapse rates in MB and PB patients cured by dapsone monotherapy were acceptably low, and most of these patients have been followed up for more than a mean incubation period of observed dapsone relapse. Along with the further extension of follow up, the risk of relapse in dapsone-cured patients will not be expected to increase. This conclusion should be considered when planning policy for the management of patients released from dapsone monotherapy. (AU)^ien. Descriptors: Hanseníase/quimioter Hanseníase/epidemiol Hanseníase/terap Dapsona/uso terap Electronic Medium: http://hansen.bvs.ilsl.br/textoc/revistas/intjlepr/1999/pdf/v67n4/v67n4a01.pdf / en Location: BR191.1

7 / 210

HANSEN

select to print Texto Completo-en

Id: 19648 Author: Pavithran, K; Bindu, V. Title: Dapsone syndrome: hepatitis-B infection a risk factor for its development?. Source: Int. J. Lepr;67(2):171-172, Jun., 1999. tab. Descriptors: Dapsona/anal Dapsona/imunol Hepatite B/compl Hepatite B/fisiopatol Hanseníase/compl Electronic Medium: http://hansen.bvs.ilsl.br/textoc/revistas/intjlepr/1999/pdf/v67n2/v67n2cor05.pdf / en Location: BR191.1

8 / 210

HANSEN

select to print Texto Completo-en

Id: 19583 Author: Chanteau, Suzanne; Cartel, Jean-Louis; Celerier, Philippe; Plichart, Régis; Desforges, Sylvie; Roux, Jean. Title: PGL-1 antigen and antibody detection in leprosy patients: evolution under chemotherapy. Source: Int. J. Lep;57(4):735-743, dec. 1989. ^btab. Abstract: Multibacillary (MB) and paucibacillary (PB) leprosy patients were tested for circulating phenolic glycolipid-I (PGL-I) antigen and antibodies before treatment. In the 27 MB patients tested, 27 (100%) were antigen positive with levels ranging from 50 to 5000 ng/ml, and 26 (96%) were antibody positive with titers ranging from 1000 to 64,000. Although the antigen and antibody levels were much higher in MB than in PB patients, we could not demonstrate a correlation between the number of acid-fast bacilli/mg of skin biopsy and these two parameters in 14 MB patients. After starting daily multidrug therapy, 10 MB patients were monitored monthly. As much as 88.75% +/- 10.8% of the PGL-I antigen was cleared from the bloodstream after 1 month while the anti-PGL-I antibody remained stable. This rapid decrease in the PGL-I antigen level strongly suggests the usefulness of this test for monitoring MB patients under chemotherapy. Descriptors: Anticorpos Antibacterianos/anal Antígenos de Bactérias/anal Dapsona/uso terap Electronic Medium: http://hansen.bvs.ilsl.br/textoc/revistas/intjlepr/1989/pdf/v57n4/v57n4a01.pdf / en Location: Br191.1

9 / 210

HANSEN

select to print Texto Completo-en

Id: 19498 Author: Matsuoka, Masanori; Kashiwabara, Yoshiko; Namisato, Masako. Title: A Mycobacterium leprae isolate resistant to dapsone rifampin, ofloxacin and sparfloxacin. Source: Int. J. Lepr;68(4):452-455, Dec., 2000. tab. Abstract: Mycobacterium leprae were isolated from a Japanese patient, and susceptibility to antileprosy drugs was examined by the mouse foot pad method. The isolate was susceptible to clofazimine and clarithromycin, and resistant to dapsone, rifampin, ofloxacin and sparfloxacin. Mutations were identified in the genes associated with resistance to these drugs. The risk of the emergence of leprosy with multidrug resistance is emphasized. (AU)^ien. Descriptors: Mycobacterium leprae/imunol Rifampina/imunol Dapsona/imunol Electronic Medium: http://hansen.bvs.ilsl.br/textoc/revistas/intjlepr/2000/pdf/v68n4/v68n4a07.pdf / en Location: BR191.1

10 / 210

HANSEN

select to print Texto Completo-en

Id: 19481 Author: Roche, Paul W; Neupane, Kapil Dev; Failbus, Sarah S; Butlin, C. Ruth. Title: Dapsone drug resistance in the MDT Era. Source: Int. J. Lepr;68(3):323-325, Sept., 2000. tab, graf. Descriptors: Dapsona/sint quim Dapsona/imunol Dapsona/uso terap Hanseníase/quimioter Electronic Medium: http://hansen.bvs.ilsl.br/textoc/revistas/intjlepr/2000/pdf/v68n3/v68n3cor02.pdf / en Location: BR191.1

11 / 210

HANSEN

select to print Texto Completo-en

Id: 19424 Author: Ji, Baohong. Title: Does dapsone resistance really matter in the MDT era?. Source: Int. J. Lepr;69(1):54-55, Mar., 2001. . Descriptors: Dapsona/imunol Dapsona/farmacol Dapsona/uso terap Hanseníase/quimioter Electronic Medium: http://hansen.bvs.ilsl.br/textoc/revistas/intjlepr/2001/pdf/v69n1/v69n1cor09.pdf / en Location: BR191.1

12 / 210

HANSEN

select to print Texto Completo-en

Id: 19386 Author: Kaur, Inderjeet; Mehta, Manjula; Agnihotri, Natini; Dogra, Sunil; Ganguly, N. K. Title: Dapsone-induced methemoglobinemia in leprosy patients. Source: Int. J. Lepr;69(3):247-249, Sept., 2001. ilus. Descriptors: Dapsona/imunol Dapsona/uso terap Metemoglobinemia/fisiopatol Hanseníase/imunol Hanseníase/fisiopatol Electronic Medium: http://hansen.bvs.ilsl.br/textoc/revistas/intjlepr/2001/pdf/v69n3/v69n3cor01.pdf / en Location: BR191.1

13 / 210

HANSEN

select to print Texto Completo-pt

Id: 18604 Author: Hadler, W. A; Ziti, L. M. Title: Algumas observações sôbre o modo de ação do 4- 4'-diaminodifenilsulfona na lepra murina / Some Observations on the mode of action of 4 - 4'-diaminodiphenyl in murine leprosy Source: Rev. bras. Leprol;24(1-2):56-68, jan-jun.- 1956. ^btab, ^bgraf. Abstract: Some aspects of the sulfone action on the murine leprosy were studied in rats, which were inoculated by the intraperitoneal route with 5, 5 mg of M. lepraemurium and then treated with 4- 4'-diamino-diphenylsulfone (DDS). The treatment was made by the oral route, 0,2 or 0,3 per cent of DDS being added to the food. The animals were divided into the following lots: Lot 1A - 20 rats treated with 0,2 per cent of DDS. Lote 1B - 20 untreated control rats. 2A - 20 rats inoculated with bacilli obtained from an animal of the lot 1A, preliminarily treated with DDS during 180 days; these animals then received 0,2 per cent of DDS mixed with the food. Lot 2B - 20 untreated control rats, which were inoculated with bacilli recovered from a rat of the lot 1B. Lot 3A - 20 rats inoculated with bacilli recovered from an animal of the lot 2A, which had previously been treated with DDS for 180 days; afterwards these animals received 0,2 per cent of DDS in the food. Lot 3B - 20 rats inoculated with the same material as the lot 3A, but afterwards treated with 0,3 per cent of DDS given with the food. Lot 3C - 20 rats inoculated with same material as the lot 3A, and kept as untreated controls. Lot 3D - 20 rats inoculated with bacilli obtained from an animal of the lot 2B; these rats were afterwards treated with DDS (0,3 per cent in the food). Lot 3E - 20 untreated control rats, inoculated with the same material as the lot 3D. The results of the treatment were based upon the survical time and the intensity of the lesions. The statistical analysis of the medium survical time in these lots of animals shows, that they constitute 3 groups. The lots which integrate these groups do not present significant difference when compared together. A first group comprises the control animals (lots 1B, 2B and 3E); a second group includes the animals inoculated with bacilli recovered from the control rats and then treated with DDS (lots 1A and 3D) and the animals inoculated with bacilli obtained from previo^ien. Descriptors: Hanseníase/quimioter Hanseníase/imunol Hanseníase/fisiopatol Hanseníase/reabil Hanseníase/terap Dapsona/sint quim Dapsona/farmacol Dapsona/uso terap Limits: Humanos Electronic Medium: http://hansen.bvs.ilsl.br/textoc/revistas/brasleprol/1956/PDF/v24n1-2/v24n1-2a06.pdf / pt Location: BR191.1

14 / 210

HANSEN

select to print

Id: 18390 Author: Ebenezer, G. J; Norman, G; Joseph, G. A; Daniel, S; Job, C. K Title: Drug resistant-Mycobacterium leprae- results of mouse footpad studies from a laboratory in South India ..- Source: s.l; s.n; 2002. 12 p. tab. Abstract: Out of 265 biopsies of leprosy patients received at the Experimental Laboratory of Schieffelin Leprosy Research and Training Centre from 1987 to 1997 for evaluating resistant strains of M. leprae using the mouse footpad technique, 49 showed resistant strains of M. leprae to varying concentration of dapsone, rifampicin and clofazimine. 23 (47%) of these were from a control area. With 369 skin-smear positive multibacillary (MB) patients as the risk group (denominator), 23 (6.23%) were resistant to one or more drugs. 18 (4.88%) had dapsone resistance, 5 (1.36%) were resistant to rifampicin and 9 (2.44%) had resistance to low concentrations of clofazimine (0.0001%). Out of the 23 biopsies with drug resistance from the control area, primary dapsone resistance was seen in 7 (30%) biopsies and secondary dapsone resistance in 11 (48%). Primary rifampicin resitance was seen in 4 (17.4%) patients, secondary rifampicin resistance in 1 (4.35%) and primary clofazimine resistance in 7 (30%). 3 (13%) of the strains showed secondary clofazimine resistance. One biopsy had resistent strains to all the three drugs. In a control area where properly supervised effective multidrug therapy (MDT) was regularly administered over the years, the emergence of drug resistance is negligible. It may not be the case if the content, duration and regularity of the drug regimen were not satisfactory. Aware of the possible shortcomings in mass administration of MDT, it is emplasized that mouse footpad studies on drug resistance should be made available at least in endemic areas where the incidence of the disease has not changed despite good MDT coverage in order to monitor the emergence of drug resistance. Research into molecular biological identification of drug resistant-M.leprae should be intensified. These steps would help to institute timely measures to check the spread of any drug-resistant organisms in the community (AU). Descriptors: MYCOBACTERIUM LEPRAE/cresc MYCOBACTERIUM LEPRAE/isol MYCOBACTERIUM LEPRAE/metab MYCOBACTERIUM LEPRAE/patogen MYCOBACTERIUM LEPRAE/ultraest RESISTÊNCIA A DROGAS DAPSONA/uso terap CLOFAZIMINA/uso terap RIFAMPINA/uso terap TESTES DE SENSIBILIDADE MICROBIANA/métodos TESTES DE SENSIBILIDADE MICROBIANA/vet - HANSENIASE/clas  HANSENIASE/compl  HANSENIASE/quimioter  HANSENIASE/imunol  HANSENIASE/microbiol  HANSENIASE/patol  OFLOXACINO/uso terap  MINOCICLINA/uso terap Limits: HUMANO Location: BR191.1; 09299/s

15 / 210

HANSEN

select to print

Id: 18385 Author: Consigny, Sophie; Bentoucha, Abdelhalim; Bonnafous, Pascale; Grosset, Jacques; Ji, Baohong Title: Bactericidal activities of HMR 3647, moxifloxacin, and rifapentine against Mycobacterium leprae in mice ..- Source: s.l; s.n; 2000. 3 p. tab. Abstract: Bactericidal activities of HMR 3647 (HMR), moxifloxacin (MXFX), and rifapentine (RPT) against Mycobacterium leprae, measured by the proportional bactericidal technique in the mouse footpad system, were compared with those of the established antileprosy drugs clarithromycin (CLARI), ofloxacin (OFLO), and rifampin (RMP. Administered in five daily doses of 100 mg/kg of body weight, HMR appeared slightly more bactericidal than CLARI. In a single dose, MXFX at 150 mg/kg was more active than the same dose of OFLO and displayed exactly the same level of activity as RMP at 10 mg/kg; the combination MXFX-minocycline (MINO) (MM) was more bactericidal than the combination OFLO-MINO (OM); RPT at 10mg/kg was more bactericidal than the same dose of RMP and even more active than the combination RMP-OFLO-MINO (ROM); the combination RPT-MXFX-MINO (PMM) killed 99.9% of viable M. leprae and was slighthy more bactericidal than RPT alone, indicating that the combination PMM showed an additive effect against M. leprae (AU). Descriptors: HANSENIASE/quimioter HANSENOSTATICOS/admin HANSENOSTATICOS/farmacol HANSENOSTATICOS/farmacocin HANSENOSTATICOS/uso terap MYCOBACTERIUM LEPRAE TESTES DE SENSIBILIDADE MICROBIANA/métodos DROGAS EM INVESTIGACAO/admin DROGAS EM INVESTIGACAO/anal DROGAS EM INVESTIGACAO/uso terap - BACTERICIDAS  QUIMIOTERAPIA COMBINADA  MYCOBACTERIUM LEPRAE/metab  MYCOBACTERIUM LEPRAE/fisiol  DAPSONA/uso terap  RIFAMPINA/uso terap  CLOFAZIMINA/uso terap  OFLOXACINO/uso terap  MINOCICLINA/uso terap  CLARITROMICINA/uso terap Limits: ESTUDO COMPARATIVO Location: BR191.1; 09311/s

16 / 210

HANSEN

select to print

Id: 18384 Author: Biswas, S; Mondal, K. K Title: Multidrug therapy in leprosy can prevent relapse- a retrospective study ..- Source: s.l; s.n; 2002. 6 p. . Abstract: A retrospective study was done at the Leprosy Control Unit (LCU) in Durgapur of Burdwan district, West Bengal, to determine the relapse rate following multidrug therapy (MDT). A total of 1581 patients (1276 PB and 305 MB) completed MDT regimens during a period of 5 years as per WHO recommendations and National Leprosy Eradication Programme (NLEP) guidelines. The treated patients were kept under surveillance as per NLEP guidelines and searched for relapses. The results of MDT were compared with those of pre-MDT (monotherapy) era at the same centre (total: 405 patients; PB-373, MB-32) andalso with those of the Leprosy Clinic in Gopalpur (only dapsone was given to a total of 189 patients, PB-167, MB-22) Following monotherapy, the relapse rate was 10.06% at the Gopalpur Leprosy Clinic and 12.4% at the Dargapur LCU during the 2 years (PB) and 5 years (MB) of surveillance, whereas following MDT no relapse case was encountered both in PB and MB cases during the surveillance periods recommended by WHO. The results of this study are comparable with those of ohter studies. Though a few studies showed relapses during long-term surveillance beyond the periods recommended by WHO, it is once again established that MDT can prevent relapse in leprosy (AU). Descriptors: HANSENIASE/quimioter HANSENIASE/epidemiol HANSENIASE/prev RECIDIVA/prev - HANSENOSTATICOS/admin  HANSENOSTATICOS/hist  HANSENOSTATICOS/normas  HANSENOSTATICOS/uso terap  CLOFAZIMINA/uso terap  DAPSONA/uso terap  RIFAMPINA/uso terap Limits: ESTUDO COMPARATIVO HUMANO Location: BR191.1; 09310/s

17 / 210

HANSEN

select to print

Id: 18365 Author: Surur, S. P Title: Drug eruptions and drug reactions ..- Source: s.l; s.n; 2003. 2p p. . Descriptors: ERUPCAO POR DROGA/clas ERUPCAO POR DROGA/compl ERUPCAO POR DROGA/diag ERUPCAO POR DROGA/etiol PREPARACOES FARMACÊUTICAS/ef adv ERUPCAO POR DROGA/terap - METOTREXATO/ef adv  DAPSONA/ef adv  HANSENIASE/diag Limits: HUMANO Location: BR191.1; 00896/s

18 / 210

HANSEN

select to print

Id: 18329 Author: Fasal, P Title: Leprosy occurs everywhere ?- Source: San Francisco; s.n; 1965. 7p p. ilus. Abstract: Leprosy can occur at all ages, in both sexes and in every race. It can be found in any geographic area and can simulate many diseases, especially those affecting the skin. The lepromatous type indicates less host resistance than the tuberculoid type. Histopathologic examination of a properly stained specimen obtained by skin biopsy is the most important diagnostic procedure. Treatment consist of long-term chemotherapy with sulfone drugs. Descriptors: HANSENIASE/clas HANSENIASE/compl HANSENIASE/diag HANSENIASE/epidemiol HANSENIASE/imunol HANSENIASE/terap HANSENIASE/transm HANSENIASE DIMORFA/diag HANSENIASE TUBERCULOIDE/diag HANSENIASE VIRCHOWIANA/diag HANSENIASE/patol DAPSONA/admin DAPSONA/uso terap - DISTRIBUICAO ESPACIAL  ANTIGENO DE MITSUDA/admin  ANTIGENO DE MITSUDA/anal  BIOPSIA/util Limits: HUMANO Location: BR191.1; 00198/s

19 / 210

HANSEN

select to print

Id: 18326 Author: Gokhale, N. R; Sule, R. R; Gharpure, M. B Title: Dapsone syndrome ..- Source: s.l; s.n; 1992. 3p p. . Descriptors: DAPSONA/admin DAPSONA/ef adv DAPSONA/farmacol DAPSONA/farmacocin DAPSONA/tox DAPSONA/uso terap - HANSENIASE/terap  QUIMIOTERAPIA COMBINADA Limits: HUMANO Location: BR191.1; 01165/s

20 / 210

HANSEN

select to print

Id: 18325 Author: Pares, Y Title: La lepre: vers une nouvelle approche thérapeuthique pharmacopée et médicine traditionnelles perspective d'avenir ?- Source: Senegal; s.n; 1980. 12p p. . Descriptors: HANSENIASE/hist HANSENIASE/terap HANSENOSTATICOS/clas HANSENOSTATICOS/hist HANSENOSTATICOS/farmacol - DAPSONA/hist  DAPSONA/uso terap  Aralia  ARSÊNICO/uso terap  ANTIMÔNIO/uso terap Limits: HUMANO Location: BR191.1; 00412/s

---

page 1 de 11

go to page

Refine the search

Database : HANSEN

Advanced form

Search for : Free form

		Search	in field
1			WordsTitle wordsAbstract wordsAuthorInstitutional authorSubject descriptorLimitsLanguageCountry, year publicationJournalType of literatureBibliographic levelMonography in seriesPublication typeConferenceUnique identifierLocationElectronic supportEntry dateRecord type
2	and or and not		WordsTitle wordsAbstract wordsAuthorInstitutional authorSubject descriptorLimitsLanguageCountry, year publicationJournalType of literatureBibliographic levelMonography in seriesPublication typeConferenceUnique identifierLocationElectronic supportEntry dateRecord type
3	and or and not		WordsTitle wordsAbstract wordsAuthorInstitutional authorSubject descriptorLimitsLanguageCountry, year publicationJournalType of literatureBibliographic levelMonography in seriesPublication typeConferenceUnique identifierLocationElectronic supportEntry dateRecord type

Search engine: iAH powered by WWWISIS

IAH - © BIREME/PAHO/WHO Latin American and Caribbean Center on Health Sciences Information